AN2 Therapeutics, Inc.

NasdaqGS:ANTX Stock Report

Market Cap: US$99.0m

AN2 Therapeutics Future Growth

Future criteria checks 0/6

AN2 Therapeutics is forecast to grow earnings and revenue by 40.6% and 49.8% per annum respectively while EPS is expected to grow by 42.2% per annum.

Key information

40.6%

Earnings growth rate

42.2%

EPS growth rate

Pharmaceuticals earnings growth21.4%
Revenue growth rate49.8%
Future return on equityn/a
Analyst coverage

Low

Last updated23 Feb 2024

Recent future growth updates

Recent updates

Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

Mar 23
Here's Why We're Not Too Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Dec 05
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

Aug 20
AN2 Therapeutics (NASDAQ:ANTX) Is In A Good Position To Deliver On Growth Plans

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

May 09
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

Feb 03
We're Not Very Worried About AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Rate

We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

Oct 21
We're Hopeful That AN2 Therapeutics (NASDAQ:ANTX) Will Use Its Cash Wisely

AN2 Therapeutics secures $17.8M contract from NIH

Sep 29

We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Jul 01
We Think AN2 Therapeutics (NASDAQ:ANTX) Can Afford To Drive Business Growth

Earnings and Revenue Growth Forecasts

NasdaqGS:ANTX - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202637-44N/AN/A3
12/31/2025N/A-91N/A-804
12/31/2024N/A-85N/A-794
12/31/2023N/A-67N/A-534
9/30/2023N/A-60-44-44N/A
6/30/2023N/A-54-42-42N/A
3/31/2023N/A-49-38-38N/A
12/31/2022N/A-43-33-33N/A
9/30/2022N/A-40-35-35N/A
6/30/2022N/A-38-30-30N/A
3/31/2022N/A-35-26-26N/A
12/31/2021N/A-28-20-20N/A
12/31/2020N/A-15-5-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANTX is forecast to have no revenue next year.

High Growth Revenue: ANTX is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANTX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.